Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Discover OncologyOpen Access

Transarterial chemoembolization for advanced hepatocellular carcinoma after failure of first-line systemic treatment: a single-center case series

View Full Paper
Ask AI
Bookmark
Share

Authors

QXQingyu XuBLBin LengRYRan You

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals improved overall survival and response rates for advanced HCC patients, suggesting TACE adds value post systemic treatment failure.

Key Points

  • Overall survival improved significantly, with a median of 24 months reported in patients receiving TACE after systemic treatment failure.
  • Objective response rate was 55.6%, indicating that more than half of the patients responded positively to the treatment.
  • The median time to progression was 3.5 months, accompanied by an acceptable level of treatment-related adverse events.
  • Patients undergoing on-demand TACE alongside systemic treatment achieved disease control in 94.4% of cases.

Cite This Study

Xu et al. (2025) studied this question.

synapsesocial.com/papers/68c24236b210217d647a276ahttps://doi.org/10.1007/s12672-025-03363-9
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Radiological Response and Characteristics of Patients Diagnosed With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: An Observational Study.2025 · 1 citations
  2. 2TACE-HAIC versus TACE as Initial Regional Therapy for Unresectable Huge Hepatocellular Carcinoma (>10 cm): A Propensity Score-Matched Study2025 · 4 citations
  3. 3Combination therapy reduces transarterial chemoembolization resistance in advanced hepatocellular carcinoma2025
  4. 4Efficacy and safety of lenvatinib plus transarterial chemoembolization with or without programmed death-1 inhibitors in the treatment of intermediate or advanced hepatocellular carcinoma: a systematic review and meta-analysis2025 · 7 citations
  5. 5Clinical efficacy of hepatic arterial infusion chemotherapy combined with transhepatic arterial embolization plus lenvatinib and tislelizumab or transarterial chemoembolization combined with lenvatinib plus tislelizumab in the treatment of advanced hepatocellular carcinoma2025 · 2 citations